Philosophical and Ethical Issues at the Forefront of Neuroscience and Genetics: An Overview for Psychiatrists

Psychiatric Clinics of North America

Volumn 32, Issue 2, 2009, Pages 437-449

  Hoop, Jinger G ^a   Spellecy, Ryan ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Medical College of Wisconsin Center for the Study of Bioethics   (United States)

Author keywords

Enhancement; Genetics; Medical ethics; Neuroethics; Neuroscience; Philosophy of medicine

Indexed keywords

CENTRAL STIMULANT AGENT; CLOZAPINE; MODAFINIL; NOOTROPIC AGENT;

BEHAVIOR GENETICS; CREATIVITY; DECISION MAKING; EMOTION; FREEDOM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE TECHNOLOGY; HUMAN; MEDICAL PROFESSION; MEDICAL RESEARCH; MORALITY; NEUROIMAGING; NEUROMODULATION; NEUROSCIENCE; PHILOSOPHY OF MEDICINE; PRIORITY JOURNAL; PROFESSIONALISM; RESEARCH ETHICS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SOCIAL ASPECT;

BIOMEDICAL ENHANCEMENT; COERCION; DECISION MAKING; EMOTIONS; GENETICS; HUMANS; MIND-BODY RELATIONS (METAPHYSICS); NEUROSCIENCES; PERSONAL AUTONOMY; PHILOSOPHY, MEDICAL; PSYCHIATRY; PSYCHOPHARMACOLOGY; RISK ASSESSMENT; SOCIAL CHANGE;

EID: 66149151358     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2009.03.004     Document Type: Review

References (44)

1. Kosslyn S.M., and Andersen R.A. Frontiers in cognitive neuroscience (1992), MIT Press, Cambridge (MA)
2. Merkel R. Intervening in the brain: changing psyche and society (2007), Springer, Berlin New York
3. Insel T.R., and Lehner T. A new era in psychiatric genetics?. Biol Psychiatry 61 (2007) 1017-1018
4. Synofzik M., and Schlaepfer T.E. Stimulating personality: ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes. Biotechnol J 3 (2008) 1511-1520
5. Corrigan P.W., and Watson A.C. At issue: stop the stigma. Call mental illness a brain disease. Schizophr Bull 30 (2004) 477-479
6. Farah M.J. Emerging ethical issues in neuroscience. Nat Neurosci 5 (2002) 1123-1129
7. Illes J., and Bird S.J. Neuroethics: a modern context for ethics in neuroscience. Trends Neurosci 29 (2006) 511-517
8. Roskies A. Neuroethics for the new millennium. Neuron 35 (2002) 21-23
9. Cheshire Jr. W.P. Drugs for enhancing cognition and their ethical implications: a hot new cup of tea. Expert Rev Neurother 6 (2006) 263-266
10. Dees R.H. Better brains, better selves? The ethics of neuroenhancements. Kennedy Inst Ethics J 17 (2007) 371-395
11. Parens E. Authenticity and ambivalence: toward understanding the enhancement debate. Hastings Cent Rep 35 (2005) 34-41
12. Wolpe P.R. Treatment, enhancement, and the ethics of neurotherapeutics. Brain Cogn 50 (2002) 387-395
13. Uhl G.R., and Grow R.W. The burden of complex genetics in brain disorders. Arch Gen Psychiatry 61 (2004) 223-229
14. Faraone S., Tsuang M., and Tsuang D. Genetics of mental disorders: a guide for students, clinicians, and researchers (1999), Guilford Press, New York
15. Nuffield Council on Bioethics. Genetics and human behavior: the ethical context. Available at:. http://www.nuffieldbioethics.org/go/ourwork/behaviouralgenetics/publicat ion_311.html Accessed January 4, 2008
16. Bernet W., Vnencak-Jones C.L., Farahany N., et al. Bad nature, bad nurture, and testimony regarding MAOA and SLC6A4 genotyping at murder trials. J Forensic Sci 52 (2007) 1362-1371
17. Attitudes, knowledge and behaviour of general practitioners in relation to HIV infection and AIDS. Commonwealth AIDS Research Grant Committee working party. Med J Aust 153 (1990) 5-12 [see comments]
18. Phelan J.C. Geneticization of deviant behavior and consequences for stigma: the case of mental illness. J Health Soc Behav 46 (2005) 307-322
19. In: Crown S., and Lee A. (Eds). Ethics primer of the American Psychiatric Association (2001), American Psychiatric Association, Washington (DC)
20. Churchland P.S. Brain-wise: studies in neurophilosophy (2002), MIT Press, Cambridge (MA)
21. Casebeer W.D. Natural ethical facts: evolution, connectionism, and moral cognition (2003), MIT Press, Cambridge (MA)
22. Greene J.D., Nystrom L.E., Engell A.D., et al. The neural bases of cognitive conflict and control in moral judgment. Neuron 44 (2004) 389-400
23. Aristotle, and Irwin T. Nicomachean ethics (1985), Hackett Publishing, Indianapolis (IN)
24. Kant I., Ellington J.W., and Kant I. Uber ein vermeintes Recht aus Menschenliebe zu lügen. 3rd edition (Grounding for the metaphysics of morals with on a supposed right to lie because of philanthropic concerns) (1993), Hackett Publishing, Indianapolis (IN)
25. Kass L.R. The wisdom of repugnance. New Repub (June 2, 1997)
26. Mori M. A moralidade da reprodução assistida e da manipulação genética. Cad Saúde Pública [online] (1999) 15. Available at: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X199 9000500008&lng=en&nr Accessed March 14, 2009
27. Sahakian B., and Morein-Zamir S. Professor's little helper. Nature 450 (2007) 1157-1159
28. Savulescu J. Justice, fairness, and enhancement. Ann N Y Acad Sci 1093 (2006) 321-338
29. Elliott C. Better than well: American medicine meets the American dream (2004), W.W. Norton, New York
30. Kramer P.D. Listening to Prozac (1993), Viking, New York
31. Larkin M. Can post-traumatic stress disorder be put on hold?. Lancet 354 (1999) 1008
32. Maher B. Poll results: look who's doping. Nature 452 (2008) 674-675
33. McCabe E.R. Clinical genetics: compassion, access, science, and advocacy. Genet Med 3 (2001) 426-429
34. Teter C.J., McCabe S.E., Boyd C.J., et al. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy 23 (2003) 609-617
35. Glannon W. Psychopharmacological enhancement. Neuroethics 1 (2008) 45-54
36. Das G. Cocaine abuse in North America: a milestone in history. J Clin Pharmacol 33 (1993) 296-310
37. Parrott A.C. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology (Berl) 191 (2007) 181-193
38. Appel J.M. When the boss turns pusher: a proposal for employee protections in the age of cosmetic neurology. J Med Ethics 34 (2008) 616-618
39. Chatterjee A. Neuroethics: toward broader discussion. Hastings Cent Rep 34 (2004) 4 [author reply 4-5]
40. Buchanan A.E. From chance to choice: genetics and justice (2000), Cambridge University Press, Cambridge (UK) New York
41. Rajczi A. One danger of biomedical enhancements. Bioethics 22 (2008) 328-336
42. Warner J. Living the off-label life. NY Times (2008) A25. Available at: http://www.nytimes.com/2008/12/27/opinion/27warner.html?_r=1 Accessed December 27, 2008
43. Carmona R.H. Frontiers of knowledge in sleep and sleep disorders: opportunities for improving health and quality of life. J Clin Sleep Med 1 (2005) 83-89
44. Artazcoz L., Cortes I., Escriba-Aguir V., et al. Understanding the relationship of long working hours with health status and health-related behaviours. J Epidemiol Community Health (2009 Mar 1) [Epub ahead of print]